Roche Q1 Sales Hit by Strong Swiss Franc

Key Financial Highlights

Swiss pharmaceutical giant Roche reported a 5% decline in first-quarter sales to 14.7 billion Swiss francs. This figure was heavily influenced by unfavorable foreign exchange rates. However, at constant exchange rates, the company posted a 6% sales growth, meeting analyst expectations and showcasing strong underlying operational performance.

Divisional Performance and Growth Drivers

The Pharmaceuticals division was a key performer, with sales growing 7% on a constant currency basis. This growth was driven by high demand for key drugs, including a 13% sales increase for the haemophilia treatment Hemlibra and a 6% rise for the multiple sclerosis drug Ocrevus. The Diagnostics division also saw a 3% sales increase at constant currencies, successfully offsetting the impact of pricing reforms in China.

Impact of Currency and Market Challenges

The primary headwind for Roche's reported earnings was the strength of the Swiss franc against currencies like the U.S. dollar, which diminished the value of overseas sales. Additionally, the diagnostics business continued to navigate challenges from China's pricing reforms for medical devices, although the company's CEO noted that the year-on-year impact is diminishing.

Conclusion and Future Outlook

Despite the currency challenges, Roche reaffirmed its full-year guidance. The company anticipates sales growth in the mid-single-digit range and growth in adjusted earnings per share in the high-single-digit range for the full year. This confident outlook reflects the strong performance of its core product portfolio and an expected improvement in the diagnostics market in the second half of the year.

FAQ

Q: Why did Roche's reported sales fall in Q1 2024?
A: Sales fell 5% primarily due to unfavorable foreign exchange effects, where a strong Swiss franc decreased the value of international sales when converted.

Q: Which products were the main growth drivers for Roche?
A: Key growth drivers included Hemlibra for haemophilia, Ocrevus for multiple sclerosis, and Xolair for asthma, which saw sales jump 26%.

Q: What is Roche's financial forecast for the rest of the year?
A: Roche confirmed its full-year forecast, expecting sales to grow in a mid-single-digit range and adjusted earnings per share to grow in a high-single-digit range.

Source: Investing.com